YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Pharmacokinetic Interaction between Verapamil and Tamoxifen in Rats

베라파밀과 타목시펜의 약물동태학적 상호작용

  • Published : 2005.10.01
Download PDF
⟨ Previous Next ⟩

Abstract

The aim of this study is to investigate the effects of verapamil on the pharmacokinetics of tamoxifen following oral administration of tamoxifen with verapamil to rats. Tamoxifen (10 mg/kg) was administered orally in the presence or absence of verapamil (1, 3 or 6 mg/kg). Compared to the control group (given tamoxifen alone), the presence of verapamil significantly (p<0.05 by 1 mg/kg, p<0.01 by 3 and 6 mg/kg) increased the areas under the plasma concentration-time curve (AUC) and the peak concentrations ($C_{max}$) of tamoxifen. Consequently, the relative bioavailability ($RB\%$) of tamoxifen with verapamil was 1.6-2.1 fold higher than that of the control. But the time to reach peak concentration ($T_{max}$) and the terminal half-life ($t_{1/2}$) of tamoxifen were not altered significantly in the presence of verapamil. The increased AUC and $C_{max}$ of tamox­ifen in the presence of verapamil might be associated with the inhibition by verapamil of the P-glycoprotein and the first­pass metabolizing enzyme CYP3A4 in small intestinal mucosa. The drug interaction should be taken into consideration when tamoxifen is used to the patient with verapamil in the clinical setting.

Keywords

References

  1. Stone, R. : NIH fends off critics of tamoxifen study. Science 258, 734 (1992) https://doi.org/10.1126/science.1359643
  2. Powles, T. J. : The case for clinical trials of tamoxifen for prevention of breast cancer. Lancet. 340, 1145 (1992) https://doi.org/10.1016/0140-6736(92)93162-G
  3. Jaiyesirni, I. A. Buzdar, A. U. Decker, D. A. and Hortobagyi, G. N. : Use of tamoxifen for breast cancer: twenty-eight years later. J Clin. Oncol. 13, 513 (1995) https://doi.org/10.1200/JCO.1995.13.2.513
  4. Robinson, E. Kimmick, G. G. and Muss, H. B. : Tamoxifen in postmenopausal women a safety perspective. Drugs Aging. 8, 329 (1996) https://doi.org/10.2165/00002512-199608050-00002
  5. Swenberg, J. A. : Clinical relevance of laboratory and animal data on tamoxifen. Oncology (Huntingt) 11, 39 (1997)
  6. Buckley, M. T. and Goa, K L. : Tamoxifen: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Clin. Pharmacokin. 37, 451 (1989)
  7. Lim, C. K. Yuan, Z. X. Lamb, J. H. White, I. N. H. De Matteis, F. and Smith, L. L. : A comparative study of tamoxifen metabolism in female rat, mouse and human liver microsomes. Carcinogenesis. 15, 589 (1994) https://doi.org/10.1093/carcin/15.4.589
  8. Jacolot, F., Simon, I., Dreano, I., Beaune, P., Riche, C. and Berthou, F. : Identification of the cytochrome P450 IIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem. Pharmacol. 41, 1911 (1991) https://doi.org/10.1016/0006-2952(91)90131-N
  9. Mani, C., Gelboin, H. V., Park, S. S., Pearce, R., Parkinson, A. and Kupfer, D. : Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P450-catalysed N-demethylation and 4-hydroxylation. Drug Metab. Dispos. 21, 645 (1993)
  10. Mani, C., Pearce, R., Parkinson, A. and Kupfer, D. : Involvement of cytochrome P4503A in catalysis of tamoxifen activation and covalent binding to rat and human liver microsomes. Carcinogenesis. 15, 2715 (1994) https://doi.org/10.1093/carcin/15.12.2715
  11. Berthou, F., Dreano, Y., Belloc, C., Kangas, L., Gautier, J. C. and Beaune, P. : Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes. Biochem. Pharmacol. 47, 1883 (1994) https://doi.org/10.1016/0006-2952(94)90319-0
  12. Dehal, S. S. and Kupfer, D. : Cytochrome P-450 3A and 2D6 catalyze ortho hydroxylation of 4-hydroxytamoxifen and 3-hydroxytamoxifen (droloxifene) yielding tamoxifen catechol: involvement of catechols in covalent binding to hepatic proteins. Drug. Metab. Dispos. 27, 681 (1999)
  13. Simon, I., Berthou, F., Riche, C., Beaune, P. and Ratanasavanh, D. : Both cytochromes P4501Al and 3A4 are involved in the N-demethylation of tamoxifen, In: Proceedings of the Fifth European ISSX Meeting Tours, France, Abstract No. 44 (1993)
  14. Mani, C., Gelboin, H. V., Park, S. S., Pearce, R., Parkinson, A. and Kupfer, D. : Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation. Drug Metab. Dispos. 21, 645 (1993)
  15. Crewe, H. K., Ellis, S. W., Lennard, M. S. and Tucker, G. T. : Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem. Pharmacol. 53, 171 (1997) https://doi.org/10.1016/S0006-2952(96)00650-8
  16. Daniel, P. C., Gaskell, J., Bishop, H., Campbell, C. and Nicholson, R. : Determination of tamoxifen and biologically active metabolites in human breast tumour and plasma. Eur. J. Cancer Clin. Oncol. 17, 1183 (1981) https://doi.org/10.1016/S0277-5379(81)80022-3
  17. Jordan, V. C., Collins, M. M., Rowsby, L. and Prestwich, G. : A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J. Endocrinol. 75, 305 (1977) https://doi.org/10.1677/joe.0.0750305
  18. DeGregorio, M. W., Coronado, E. and Osborne, C. K. : Tumor and serum tamoxifen concentrations in the athymic nude mice. Cancer Chemother. Pharmacol. 23, 68 (1989) https://doi.org/10.1007/BF00647244
  19. Robinson, S. P., Langan-Fahey, S. M. and Jordan, V. C. : Implications of tamoxifen metabolism in the athymic mouse for the study of antitumor effects upon human breast cancer xenografts. Eur. J. Cancer Clin. Oncol. 25, 1769 (1989) https://doi.org/10.1016/0277-5379(89)90347-7
  20. Gant, T. W., O'Connor, C. K., Corbitt, R., Thorgeirsson, U. and Thorgeirsson, S. S. : In vivo induction of liver P-glycoprotein expression by xenobiotics in monkeys. Toxicol. Appl. Pharmacol. 133, 269 (1995) https://doi.org/10.1006/taap.1995.1151
  21. Rao, U. S., Fine R. L. and Scarborough, G. A. : Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem. Pharmacol. 48, 287 (1994) https://doi.org/10.1016/0006-2952(94)90099-X
  22. Thiebaut, F., Tsuruo, T., Hamada, H., Cottesman, M. M., Pastan, I. and Willingham, M. C. : Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. U.S.A. 84, 7735 (1987)
  23. Cordon-Cardo, C., O'Brien, J. P., Casals, D., Rittman-Grauer, L., Biedler, J. L., Melamed, M. R. and Bertino, J. R. : Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. U.S.A. 86, 695 (1989)
  24. Sugawara, I., Kataoka, I., Morishita, Y., Hamada, H., Tsuruo, T., Itoyama, S. and Mori, S. : Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res. 48, 1926 (1988)
  25. Gottesman, M. M. and Pastan, I. : Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62, 385 (1993) https://doi.org/10.1146/annurev.bi.62.070193.002125
  26. Gan, L.-S. L., Moseley, M. A., Khosla, B., Augustijns, P. E, Bradshaw, T. P., Hendren, R. W. and Thakker, D. R. : CYP3A-Like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells: interaction between the two biochemical barriers to intestinal transport. Drug Metab. Dispos. 24, 344 (1996)
  27. Watkins, P. B. : The barrier function of CYP3A4 and Pglycoprotein in the small bowel. Adv. Drug Deliv. Rev. 27, 161 (1996) https://doi.org/10.1016/S0169-409X(97)00041-0
  28. Wacher, V. H., Silverman, J. A., Zhang, Y. and Benet, L. Z. : Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of pep tides and peptidomimetics. J. Pharm. Sci. 87, 1322 (1998) https://doi.org/10.1021/js980082d
  29. Ito, K., Kusuhara, H. and Sugiyama, Y. : Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption theoretical approach. Pharm. Res. 16, 225 (1999) https://doi.org/10.1023/A:1018872207437
  30. Reynolds, J. E. F. : Martindale - The Extra Pharmacopeia, Pharmaceutical Press. London (1993)
  31. Krikler, D. M. and Spurrell, R. A. : Verapamil in the treatment of paroxysmal supraventricular tachycardia. Postgrad. Med. J. 50, 447 (1974) https://doi.org/10.1136/pgmj.50.585.447
  32. Gould, B. A., Mann, S., Kieso, H., Subramanian, V. B. and Raftery, E. B. : The 24-hour ambulatory blood pressure profile with verapamil. Circulation 65, 22 (1982) https://doi.org/10.1161/01.CIR.65.1.22
  33. Lewis, G. R., Morley, K. D., Lewis, B. M. and Bones, P. J. : The treatment of hypertension with veraparnil, N. Z. Med. J. 87, 351 (1978)
  34. Leveque, D. and Jehl, F. : P-glycoprotein and pharmacokinetics. Anticancer Res. 15, 331 (1995)
  35. Burton, P. S., Conradi, R. A., Hilgers, A. R. and Ho, N. F. : Evidence for a polarized efflux for peptides in the apical membrane of Caco-2 cells. Biochem. Biophys. Res. Commun. 190, 760 (1993) https://doi.org/10.1006/bbrc.1993.1114
  36. Hunter, J., Jepson, M. A., Tsuruo, T., Simmons, N. L. and Hirst, B. H. : Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators. J. BioI. Chem. 268, 14991 (1993)
  37. Zhou, S., Yung Chan, S., Cher Goh, B., Chan, E., Duan, W., Huang, M. and McLeod, H. L. : Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin. Pharmacokinet. 44, 279 (2005) https://doi.org/10.2165/00003088-200544030-00005
  38. Magnarin, M., Morelli, M., Rosati, A., Bartoli, F., Candussio, L., Giraldi, T. and Decorti. G. : Induction of proteins involved in multidrug resistance (P-glycoprotein, MRP1, MRP2, LRP) and of CYP 3A4 by rifampicin in LLC-PKI cells. Eur. J. Pharmacol. 483, 19 (2004) https://doi.org/10.1016/j.ejphar.2003.10.010
  39. Choi, J. S. and Kim, H. J. : Pharmacokinetic interaction between diltiazem and paclitaxel in rats. J. Kor. Pharm. Soc. 33, 299 (2003)
  40. Choi J. S. and Lee, C. K. : Pharmacokinetic interaction between nifedipine and paclitaxel in rats. J. Pharm. Soc. Korea 48, 61 (2004)
  41. Scambia, G., Ranelletti, F.O., Panici, P. B., De Vincenzo, R., Bonanno, G., Frrandina, G., Paiantelli, M., Bussa, S., Rumi, C. and Cianfriglia, M. et al. : Quercetin potentiates the effect of adriamycin in a multidurg-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. Cancer Chemother. Pharmacol. 36, 459 (1994) https://doi.org/10.1007/BF00685794
  42. Choi, J. S., Jo, B. W. and Kim, Y. C. : Enhanced bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin. Eur. J Pharm. Biopharm. 57, 313 (2004) https://doi.org/10.1016/j.ejpb.2003.11.002
  43. Zhang, H., Wong, C. W., Coville P. F. and Wanwimolruk, S. : Effect of the grapefruit flavonoid naringin on pharmacokinetics of quinine in rats. Drug Metabol. Drug Interact. 17, 351 (2000)
  44. Candussio, L., Decorti, G., Crivellato, E., Granzotto, M., Rosati, A., Giraldi, T. and Bartoli, F. : Toxicologic and pharmacokinetic study of low doses of verapamil combined with doxorubicin. Life Sci. 71, 3109 (2002) https://doi.org/10.1016/S0024-3205(02)02175-6
  45. Kerr, D. J., Graham, J., Cummings, J., Morrison, J. G., Thompson, G. G., Brodie, M. J. and Kaye, S. B. : The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother. Pharmacol. 18, 239 (1986)
  46. Fried, K. M. and Wainer, I. W. : Direct determination of tamoxifen and its four major metabolites in plasma using coupled column high-performance liquid chromatography. J. Chromatogr. B. Biomed. Appl. 655, 261 (1994) https://doi.org/10.1016/0378-4347(94)00054-9
  47. Rocci, M. L. and Jusko, W. J. : LAGRAN program for area and moments in pharmacokinetic analysis. Computer Programs in Biomedicine 16, 203 (1983) https://doi.org/10.1016/0010-468X(83)90082-X
  48. Choi, J. S. and Li, X. : The effect of verapamil on the pharmacokinetics of paclitaxel in rats. Eur. J. Pharm. Sci. 24, 95 (2005) https://doi.org/10.1016/j.ejps.2004.10.002
  49. Verschraagen, M., Koks, C. H., Schellens, J. H. and Beijnen, J. H. : P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil. Pharmacol. Res. 40, 301 (1999) https://doi.org/10.1006/phrs.1999.0535
  50. Hotta, T., Tanimura, H., Yamaue, H., Iwahashi, M., Tani, M., Tsunoda, T., Tarnai, M., Noguchi, K., Mizobata, S., Arii, K. and Terasawa, H. : Tamoxifen circumvents the multidrug resistance in fresh human gastrointestinal cancer cells. J. Surg. Res. 66, 31 (1996) https://doi.org/10.1006/jsre.1996.0368
  51. Shao, Y. M., Ayesh, S. and Stein, W. D. : Mutually co-operative interactions between modulators of P-glycoprotein. Biochim. Biophys. Acta. 1360, 30 (1997) https://doi.org/10.1016/S0925-4439(96)00065-8